The BioCentury Show

Hosted by BioCentury

Business ScienceInterviews guests

Website RSS feed

Episodes

Latest episode

Jun 2026

Language

EN-US

About the show

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast .

Listen to episodes

60 recent

June 12, 2026Episode 11136 min

Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner

ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The BioCentury Show, Genge discusses progress in pathway prioritization, progression-rate prediction, and endpoint standardization with BioCentury's Selina Koch.On the biology side, Genge expects the field to converge on a small number of high-priority pathways. SOD1 is the first validated example, and AL-S Pharma is now testing whether misfolded SOD1 marks a treatable subset of sporadic ALS. On biomarkers, she's optimistic a TDP-43 marker could arrive within two years.View full story: https://www.biocentury.com/article/659713 #ALS #DrugDevelopment #ClinicalTrials #Biomarkers #ALSResearch00:00 - Introduction02:03 - ALS Mechanistic Diversity06:13 - Trial Design Challenges16:52 - Biomarker Toolkit Update24:20 - ALS Pharma & SOD1

May 28, 2026Episode 11037 min

Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China

Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing that millions of patients have benefited from the company’s medicines. He has led PDUFA reauthorization negotiations for industry, chaired BIO, and advocated for the interests of mid-sized biotechs.As Pops prepares to retire as CEO (he will remain chairman), he spoke with BioCentury Washington Editor Steve Usdin about the ways policy and economics shape the development of medicines. Pops discussed the impact of the Trump administration’s most favored nation (MFN) drug pricing policy and the Inflation Reduction Act (IRA), concerns about FDA’s loss of talent, and competition and collaboration with China’s life sciences sector.View full story: https://www.biocentury.com/article/659601#DrugPricing #BiotechLeadership #FDAPolicy #LifeSciencesPolicy #DrugDevelopment00:00 - Introduction01:40 - Alkermes’ Evolution05:12 - PBMs, Pricing & Access10:54 - IRA18:14 - MFN24:36 - PDUFA Negotiations28:05 - FDA Staffing31:40 - China & U.S. Policy

May 15, 2026Episode 10936 min

Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.”In a wide-ranging interview on The BioCentury Show with BioCentury Washington Editor Steve Usdin, Knudsen discussed the Parker Institute’s focus on accelerating the path from scientific breakthrough to medical impact.As it approaches its tenth anniversary, the institute has deployed about $400 million, catalyzing roughly $4 billion in follow-on investment across 17 companies.View full story: https://www.biocentury.com/article/659476#CancerImmunotherapy #TranslationalScience #DrugDevelopment #Biopharma #CancerResearch00:00 - Introduction01:34 - Optimizing Translation07:42 - Training the Immune System16:33 - China’s Opportunity20:50 - Need for a Cancer Strategy24:40 - Enhancing Cancer Survivorship27:55 - Scientific Foundation Under Threat

May 1, 2026Episode 10833 min

Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy

A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, according to Syncona CEO Chris Hollowood.Hollowood spoke on The BioCentury Show with Editor in Chief Simone Fishburn about how discovery is evolving, why causal biology has been stuck in a loop of circularity, and where the U.K. investor is headed. He also discussed the firm’s approach to gene therapy investments, how it is surmounting the field’s challenges and Syncona’s pivot last year, with a portfolio shift from 25% to over 85% clinical-stage companies.View full story: https://www.biocentury.com/article/659341#CausalBiology #GeneTherapy #BiotechInvesting #DrugDiscovery #ClinicalStage00:00 - Introduction01:06 - Rational Target Discovery16:48 - Gene Therapy23:15 - Syncona’s Strategy

April 17, 2026Episode 10737 min

Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing

The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-founder and managing director Sander Slootweg says there’s still more that can be done to fund future European innovations and improve Europe’s competitiveness globally.“We’ve observed in Europe that although we see great science, and we’ve been able to build great companies, in terms of the absolute magnitude of the ecosystem, we’re still lagging behind the U.S., and also China is coming up quickly,” Slootweg said in conversation with BioCentury's Stephen Hansen.View full story: https://www.biocentury.com/article/659150#EuropeanBiotech #VentureCapital #BiotechFunding #Bioeconomy #GlobalInnovation00:00 - Introduction01:34 - Forbion’s growth05:35 - Deal flow in Europe10:20 - Green Investing14:24 - Sourcing Asia Deals22:20 - Unlocking the EU’s Capital27:54 - Speeding Up Trials30:13 - Building a Thriving EU Market34:38 - Central & Eastern Europe

April 3, 2026Episode 10633 min

Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform

The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting serious efforts into solving.Mahony, one of the major influential figures in U.K. biotech, is a senior partner in growth investments at Novo Holdings, and was until December chair of the U.K.’s BioIndustry Association (BIA). In conversation with BioCentury Editor in Chief Simone Fishburn on The BioCentury Show, Mahony discussed the future of U.K. and European biotech, and the intersection of reforms related to financing and clinical trials, as well as the need for a rethink on drug pricing.View full story: https://www.biocentury.com/article/658997#UKBiotech #BiotechInnovation #DrugPricing #HealthcareReform #LifeSciencesPolicy00:00 - Introduction01:40 - U.K. Clinical Trial Reform04:23 - Funding U.K. Biotech10:40 - Propagating Innovation15:08 - Measuring Progress18:22 - Drug Pricing22:40 - Scaling Europe’s Biotechs25:16 - AI in Biotech

March 20, 2026Episode 10539 min

Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers

As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI is showing measurable value now, how public techbio companies are being pushed toward proof points, and what comes next — from out-of-domain prediction to stronger data foundations and precompetitive collaboration.View full story: https://www.biocentury.com/article/658829#ArtificialIntelligence #DrugDevelopment #AgenticAI #ClinicalProof #BiopharmaInnovation00:00 - Introduction01:41 - AI Hype to Proof04:52 - Where AI Adds Value13:30 - AI for Clinical Trials17:01 - Agentic AI in R&D25:34 - Out-of-Domain Prediction28:24 - Future of Techbio31:13 - Precompetitive Consortia35:24 - CEO Leadership and Catalysts

March 6, 2026Episode 10435 min

Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity

There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much slower relative to the broader healthcare environment, SoftBank’s Jacqueline Fok said on The BioCentury Show.In conversation with BioCentury's Stephen Hansen, Fok, who is investment director, Life Sciences & Health Tech at SoftBank Investment Advisers, also detailed SoftBank’s investment strategy in life sciences and the opportunity the U.K. has to stand out as a globally competitive player, with SoftBank’s obesity portfolio company Metsera as a recent example of success.View full story: https://www.biocentury.com/article/658661#ArtificialIntelligence #DrugDevelopment #BiotechInvestment #UKBiotech #ObesityDrugDevelopment00:00 - Introduction01:30 - SoftBank Strategy08:40 - Metsera14:48 - U.K. Biotech21:38 - AI28:20 - Women in Leadership32:03 - Fok’s Catalysts

February 18, 2026Episode 10340 min

Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development

Caution: This episode of The BioCentury Show contains strong language.In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slowing drug development and pushing companies to launch early-stage trials outside the U.S.In conversation with BioCentury Washington Editor Steve Usdin, Kolchinsky also discusses U.S. policy headwinds, including most-favored-nation (MFN) pricing proposals and the Inflation Reduction Act’s “pill penalty,” and why he’s concerned that the biopharma sector is too “genteel” in its advocacy. Kolchinsky explains his decision to speak publicly about regulatory and political issues, including immigration, and reflected on China’s expanding role in the global life sciences innovation ecosystem.View full story: https://www.biocentury.com/article/658433#BiotechPolicy #FDALeadership #DrugPricingPolicy #LifeSciencesInnovation #CapitalMarkets00:00 - Introduction00:37 - Impact of FDA Policy Changes06:17 - MFN & Drug Pricing in Europe20:16 - The Importance of Speaking Up34:26 - China & Innovation

February 6, 2026Episode 10240 min

Ep. 102 - Psychiatry R&D: Steve Paul on Serendipity, Engineering and What Drives Real Breakthroughs

With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery, selectivity and tolerability fixes are turning long-standing hypotheses into usable medicines, says veteran CNS drug developer Steven Paul. Few drug developers have had a closer view of the field’s false starts — and occasional breakthroughs — than Paul, who has moved from NIH to pharma R&D leadership and now to company building at Karuna, acquired by BMS for $14 billion, and Seaport.In conversation with The BioCentury Show's Selina Koch, Paul explains why serendipity still plays a disproportionate role in psychiatric drug development and how critical it is for teams to engineer and execute their way from an unexpected signal to a usable medicine. He also discusses psychedelics, brain shuttles, Karuna’s muscarinic approach in schizophrenia, and the delivery and trial-design choices Seaport is using to revisit neuroactive steroid biology in depression.View full story: https://www.biocentury.com/article/658314#PsychiatryTherapeutics #CNSDrugDevelopment #BiotechEngineering #Psychedelics #NeuroScience00:00 - Introduction01:32 - Psychiatric Drug Discovery06:56 - The Karuna Story22:09 - What’s New in Depression32:06 - Gene Therapies, Brain Shuttles33:53 - Psychedelics